Treximet for Prevention of Post Traumatic Headache Associated With

Status Terminated

Clinical Trial Summary

This study will evaluate the effectiveness of Treximet when taken for post traumatic headache by measuring any change in the number of headache days or any change in a subject's ability to think following treatment with study medication. Eligible subjects will complete 3 visits. Following Visit 1, subjects will treat with their usual medication and document headache symptoms and therapy in a Headache Diary. After 30 days, subjects will return for Visit 2 and be randomized (like the flip of a coin) to receive Treximet or matching placebo to treat at the same time each day. Treximet will be provided to treat any headache that occurs. Subjects will complete a daily Diary. After 30 days, subjects will exit the study at Visit 3.

Clinical Trial Description

Subjects will be enrolled at 3 investigative sites. At Visit 1, a medical, headache, and medication history will be collected and a physical and neurological exam with vital signs will be performed. An ECG will be completed if one has not been completed in the previous 6 months. Subjects will be administered a series of psychological tests to help the study doctor decide whether or not a subject is eligible. The Headache Impact Test-6 and Migraine Specific Quality of Life Questionnaire will be completed at each visit. During a 30-day Baseline Period, subjects will treat with their usual medication and complete a daily Diary documenting headache symptoms and treatment. At Visits 2 and 3 subjects will complete the Mental Efficiency Workload Test and Migraine Early Warning Tool. Following randomization at Visit 2, subjects will treat daily for 30 days with Treximet or a matching placebo. Subjects will be provided with Treximet for rescue of any persisting or recurring headache. During the Treatment Period, subjects will complete a daily Diary reporting headache symptoms and response to treatment. After the 30-day Treatment Period, subjects will exit the study at Visit 3 . ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01053507
Study type	Interventional
Source	Cady, Roger, M.D.
Contact
Status	Terminated
Phase	Phase 4
Start date	May 2010
Completion date	November 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04369729` - Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache
Completed	`NCT03588364` - The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine	N/A
Recruiting	`NCT05378074` - Hypersensitivity to Opening of BKCa Channels in Post-Traumatic Headache	N/A
Recruiting	`NCT05328635` - Post-traumatic Headache Multidisciplinary Study
Recruiting	`NCT04776304` - Art Therapy qEEG Study for Service Members With a Traumatic Brain Injury and Posttraumatic Stress Symptoms	N/A
Recruiting	`NCT04614922` - Acceptance and Commitment Therapy-based Rehabilitation of Post-concussion Symptoms	N/A
Recruiting	`NCT05595993` - Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache	N/A
Completed	`NCT03674398` - Aerobic Exercise and Cognitive Training Effects on Postconcussive Symptomology	N/A
Completed	`NCT02965027` - Prazosin for Post-Concussive Headaches	Phase 4
Active, not recruiting	`NCT05635656` - Digital Solutions for Concussion	N/A
Recruiting	`NCT06015451` - Exercise in Postconcussion Symptoms and Posttraumatic Headache	N/A
Recruiting	`NCT04906603` - Theta Burst Stimulation for Headaches After Traumatic Brain Injury	N/A
Completed	`NCT02419131` - Cognitive-Behavior Therapy for Posttraumatic Headache	N/A
Terminated	`NCT03806985` - Effects of Psilocybin in Concussion Headache	Phase 1
Completed	`NCT05243953` - Hypersensitivity to Opening of ATP-Sensitive Potassium Channels in Post-Traumatic Headache	N/A
Completed	`NCT03056352` - Metoclopramide for Post-Traumatic Headache. A Pilot Study	Phase 1/Phase 2
Recruiting	`NCT06132529` - A Study to Evaluate Biomarker Signature to Predict the Persistence of Post-traumatic Headache
Completed	`NCT01854385` - Sumatriptan as Treatment for Post-traumatic Headache	Phase 2
Completed	`NCT03523923` - TBI Care: Collaborative Care for Pain After Traumatic Brain Injury (TBI)	N/A
Recruiting	`NCT05378061` - Hypersensitivity to PACAP-38 in Post-Traumatic Headache	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms